

Supplement Table 1. Evaluation of differences between influenza subtypes.

	H1N1 (n=12) n (%)	H3N2 (n=22) n (%)	<i>p</i>
Age, median (IQR)	70 (58.25-79.75)	66 (53.75-80)	0.901
Male	3 (25)	7 (31.8)	0.674
Female	9(75)	15(68.2)	
Fever	9 (75)	12 (54.5)	0.233
Weakness	10 (83.3)	18 (81.8)	0.912
Myalgia	3 (25)	8 (36.4)	0.494
Headache	2 (16.7)	9 (40.9)	0.136
Cough	12 (100)	19 (86.4)	0.096
Sore throat	8 (66.7)	6 (27.3)	0.025
Dyspnea	11 (91.7)	18 (81.8)	0.421
Symptom duration, median (IQR)	4 (3-4)	3.5 (3-6)	0.711
Comorbidities	11 (91.7)	18 (81.8)	0.421
Asthma	3 (25)	3 (13.6)	0.414
DM	4 (33.3)	8 (36.4)	0.859
Solid organ malignancy	4 (33.3)	4 (18.2)	0.327
Cardiovascular disease	8 (66.7)	14 (63.6)	0.859
Hematological malignancy	0	1 (4.5)	0.346
COPD	4 (33.3)	8 (36.4)	0.859
Creatinine, median (IQR), mg/dL	1.04 (0.80-1.48)	1.06 (0.91-1.32)	0.885
WBC, median (IQR), x10 ³ /μL	6919 (3695-10,915)	8094 (5999-13,186)	0.506
Neutrophil, median (IQR), x10 ³ /μL	4822 (2773-7774)	6646 (4674-10,811)	0,525
Lymphocyte, median (IQR), x10 ³ /μL	673 (326-885)	930 (550-1910)	0,179
ALT, median (IQR), U/L	24.5 (14.5-36)	23 (14.75-31.25)	0.763
AST, median (IQR), U/L	38.5 (19.25-57.75)	31.5 (21.5-45)	0.683
CRP, median (IQR), mg/L	135 (65-218)	64.5 (23.50-105)	0.255
Vaccinated in the same season	3 (25)	5 (22.7)	0.882
Vaccinated in the previous season	6 (50)	5 (22.7)	0.104
Antiviral use	5 (41.7)	7 (31.8)	0.566
Antibiotic use	12 (100)	22 (100)	
Pneumonia	6 (50)	11 (50)	1.000
Mechanical ventilation	5 (41.7)	8 (36.4)	0.761
Intensive care hospitalization	3 (25)	5 (22.7)	0.882
Exitus	1 (8.3)	3 (13.6)	0.638

IQR: Interquartile range, **DM:** Diabetes mellitus, **COPD:** Chronic obstructive pulmonary disease, **WBC:** White blood cell, **ALT:** Alanine aminotransferase, **AST:** Aspartate aminotransferase, **CRP:** C-reactive protein.

Supplement Table 2. Evaluation of influenza-positive patients with and without pneumonia.

	Patients with pneumonia (n=19) n (%)	Patients without pneumonia (n=18) n (%)	<i>p</i>
Age, median (IQR)	73 (62.0-81.0)	68 (48.5-74.7)	0.110
Male	13 (68.4)	13 (72.2)	0.800
Female	6(31.6)	5(27.8)	
BMI	26 (22-29)	26 (22.7-33.5)	0.103
Smoking	3 (15.7)	3 (16.6)	0.673
Fever	13 (68.4)	11 (61.1)	0.642
Weakness	16 (84.2)	14 (77.7)	0.618
Myalgia	7 (36.8)	6 (33.3)	0.823
Cough	18 (94.7)	14 (77.7)	0.132
Sore throat	6 (31.5)	10 (55.5)	0.141
Headache	5 (26.3)	7 (38.8)	0.414
Dyspnea	17 (89.4)	14 (77.7)	0.335
Symptom duration, median (IQR)	4 (3-6)	4 (3-5.25)	0.378
Comorbidities	16 (84.2)	16 (88.8)	0.676
Asthma	4 (21.0)	2 (11.1)	0.408
DM	6 (31.5)	7 (38.8)	0.642
Solid organ malignancy	4 (21.0)	4 (22.2)	0.931
Cardiovascular disease	12 (63.1)	13 (72.2)	0.556
COPD	5 (26.3)	8 (44.4)	0.248
Creatinine, median (IQR), mg/dL	1.05 (0.85-1.4)	1.06 (0.95-1.29)	0.988
WBC, median (IQR), x10 ³ /uL	7680 (5314-9618)	9150 (6967-13,188)	0.488
Neutrophil, median (IQR), x10 ³ /uL	6145 (3736-7795)	6900 (4970-10,924)	0.546
Lymphocyte, median (IQR), x10 ³ /uL	674 (446-1003)	905 (483-1910)	0.267
Creatine kinase*, median (IQR), U/L	208 (66.5-325)	210 (66.7-502)	0.907
ALT, median (IQR), U/L	22 (12-30)	27 (17.5-37.2)	0.089
AST, median (IQR), U/L	32 (18-51)	29.5 (24.5-47.2)	0.627
CRP**, median (IQR), mg/L	95 (50-195)	57 (22-97.5)	0.057
Vaccinated in the same season	2 (10.5)	7 (38.8)	0.04
Vaccinated in the previous season	5 (26.3)	7 (38.8)	0.414
H1N1	6 (31.5)	6 (33.3)	0.909
H3N2	11 (57.8)	11 (61.1)	0.842
Antiviral use	10 (52.6)	5 (27.7)	0.124
Antibiotic use	19 (100)	18 (100)	
Mechanical ventilation	7 (36.8)	7 (38.8)	0.898
Intensive care hospitalization	5 (26.3)	4 (22.2)	0.772
Exitus	3 (15.7)	1 (5.5)	0.316

IQR: Interquartile range, **DM:** Diabetes mellitus, **COPD:** Chronic obstructive pulmonary disease, **WBC:** White blood cell, **ALT:** Alanine aminotransferase, **AST:** Aspartate aminotransferase, **CRP:** C-reactive protein.

*Tested in 24 patients. **Tested in 22 patients.